Quarterly ResultMay 1, 2026, 09:18 AM
IRMD Q1 Revenue $22.0M (+13%); GAAP EPS $0.45 (+22%); Dividend $0.20
AI Summary
IRADIMED CORPORATION reported strong first-quarter 2026 financial results, with revenue increasing 13% to $22.0 million and GAAP diluted EPS rising 22% to $0.45. The company also announced a regular quarterly cash dividend of $0.20 per share and reaffirmed its full-year 2026 revenue and earnings guidance. Additionally, Iradimed commercially launched its next-generation 3870 MRI-compatible IV infusion pump system, with strong early order activity.
Key Highlights
- Q1 2026 revenue increased 13% to $22.0 million from $19.5 million in Q1 2025.
- Q1 2026 GAAP diluted EPS rose 22% to $0.45 from $0.37 in Q1 2025.
- Q1 2026 non-GAAP diluted EPS increased 17% to $0.49 from $0.42 in Q1 2025.
- Declared a regular quarterly cash dividend of $0.20 per share for Q2 2026.
- Commercially launched the next-generation 3870 MRI-compatible IV infusion pump system.
- Q2 2026 revenue guidance set at $20.0 million to $21.0 million.
- Reaffirmed full-year 2026 revenue guidance of $91.0 million to $96.0 million.
- Cash flow from operations increased 93% to $8.3 million in Q1 2026.